DRESDEN, Germany, Nov. 17, 2011 /CNW/ - Cenix BioScience GmbH, a leading
discovery-stage contract research provider and technology developer
specialized in RNAi-, microRNA- and high content-driven pharmacology,
today announced that it has signed a research agreement with
Heidelberg-based SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical
company dedicated to developing innovative therapies for the treatment
of disorders of the central nervous system.
Under the research agreement's first assignment to advance the SYGNIS
KIBRA project, Cenix will apply its long-standing expertise in
combining high content screening with gene silencing analyses in cultured human cells, to establish and
optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system. Using such assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates, thereby
accelerating and enriching the SYGNIS drug development pipeline.
"We are delighted to enter into this new relationship with SYGNIS,"
noted Dr. Christophe Echeverri, CEO/CSO of Cenix. "This project, and
the many others like it now ongoing here and throughout the industry,
continue to confirm the unparalleled power of RNAi-based
experimentation for not only discovering but also validating and
de-risking new candidate drug targets".
Financial terms were not disclosed.
Cenix BioScience GmbH conducts contract research and technology
development focused on cell-based and in vivo applications of RNA interference (RNAi), miRNA modulation and high
content phenotyping to accelerate target discovery, target validation,
and the non-clinical development of new drug candidates. Since its
inception in 1999, Cenix has built up leading scientific and commercial
track records, successfully progressing therapeutic programs for
numerous industry and academic partners in a wide range of disease
fields. This success is anchored in the consistent application of
scientific and technical best practices in fully customized,
multi-staged projects designed to offer maximal strategic value with
full data transparency and carefully minimized risk. For more
information, visit the company's web site: http://www.cenix.com
SYGNIS Bioscience GmbH & Co. KG is a part of SYGNIS Pharma AG, a
specialized pharmaceutical company that focuses on the research and
development of innovative therapies for the treatment of disorders of
the central nervous system (CNS), for which there are currently no or
only inadequate therapeutic options available. In this field, SYGNIS is
concentrating on the clinical development of its drug candidate AX200
for the treatment of acute stroke and on its pre-clinical KIBRA project
for the treatment of various forms of dementia. For additional
information, visit the company's web site: http://www.sygnis.de
Cenix and the Cenix BioScience logo are registered trademarks owned by
Cenix BioScience GmbH. Definiens and Definiens XD are registered
trademarks owned by Definiens AG.
SOURCE Cenix BioScience GmbH
For further information:
Dr. Christoph Sachse, Director Cell-based Services, Cenix BioScience GmbH
T: +49-351-4173-0; F: +49-351-4173-109; E: email@example.com; W: http://www.cenix.com/